Literature DB >> 25278690

Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.

Paola Dongiovanni1, Stefano Romeo1, Luca Valenti1.   

Abstract

Hepatocellular carcinoma (HCC) is the fourth cause of cancer related mortality, and its incidence is rapidly increasing. Viral hepatitis, alcohol abuse, and exposure to hepatotoxins are major risk factors, but nonalcoholic fatty liver disease (NAFLD) associated with obesity, insulin resistance, and type 2 diabetes, is an increasingly recognized trigger, especially in developed countries. Older age, severity of insulin resistance and diabetes, and iron overload have been reported to predispose to HCC in this context. Remarkably, HCCs have been reported in non-cirrhotic livers in a higher proportion of cases in NAFLD patients than in other etiologies. Inherited factors have also been implicated to explain the different individual susceptibility to develop HCC, and their role seems magnified in fatty liver, where only a minority of affected subjects progresses to cancer. In particular, the common I148M variant of the PNPLA3 gene influencing hepatic lipid metabolism influences HCC risk independently of its effect on the progression of liver fibrosis. Recently, rare loss-of-function mutations in Apolipoprotein B resulting in very low density lipoproteins hepatic retention and in Telomerase reverse transcriptase influencing cellular senescence have also been linked to HCC in NAFLD. Indeed, hepatic stellate cells senescence has been suggested to bridge tissue aging with alterations of the intestinal microbiota in the pathogenesis of obesity-related HCC. A deeper understanding of the mechanisms mediating hepatic carcinogenesis during insulin resistance, and the identification of its genetic determinants will hopefully provide new diagnostic and therapeutic tools.

Entities:  

Keywords:  Cirrhosis; Fibrogenesis; Genetics; Hepatocellular carcinoma; Liver disease; Nonalcoholic fatty liver disease; Patatin-like phospholipase domain-containing 3; Single nucleotide polymorphism; Steatosis

Mesh:

Year:  2014        PMID: 25278690      PMCID: PMC4177475          DOI: 10.3748/wjg.v20.i36.12945

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  120 in total

1.  Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.

Authors:  Marcela Salomao; Woojin M Yu; Robert S Brown; Jean C Emond; Jay H Lefkowitch
Journal:  Am J Surg Pathol       Date:  2010-11       Impact factor: 6.394

2.  A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia.

Authors:  Angelo B Cefalù; James P Pirruccello; Davide Noto; Stacey Gabriel; Vincenza Valenti; Namrata Gupta; Rossella Spina; Patrizia Tarugi; Sekar Kathiresan; Maurizio R Averna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-30       Impact factor: 8.311

3.  Telomerase mutation: a genetic risk factor for cirrhosis.

Authors:  Roongruedee Chaiteerakij; Lewis R Roberts
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

4.  HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.

Authors:  G Nkontchou; M Ziol; M Aout; M Lhabadie; Y Baazia; A Mahmoudi; D Roulot; N Ganne-Carrie; V Grando-Lemaire; J-C Trinchet; E Gordien; E Vicaut; I Baghad; M Beaugrand
Journal:  J Viral Hepat       Date:  2011-10       Impact factor: 3.728

Review 5.  Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Hepatology       Date:  2011-05-14       Impact factor: 17.425

6.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.

Authors:  Eugenia E Calle; Carmen Rodriguez; Kimberly Walker-Thurmond; Michael J Thun
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

7.  Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.

Authors:  Joel R Pekow; Atul K Bhan; Hui Zheng; Raymond T Chung
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

8.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

9.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

Review 10.  Hepatocellular carcinoma with nonalcoholic steatohepatitis.

Authors:  Sayaka Mori; Takahiro Yamasaki; Isao Sakaida; Taro Takami; Eiki Sakaguchi; Teruaki Kimura; Fumie Kurokawa; Shiro Maeyama; Kiwamu Okita
Journal:  J Gastroenterol       Date:  2004       Impact factor: 7.527

View more
  39 in total

Review 1.  Is That Possible to Stop or Cease the NASH to Turn into HCC?

Authors:  Ahmet Uygun
Journal:  J Gastrointest Cancer       Date:  2017-09

2.  Identifying patients at risk from nonalcoholic fatty liver-related hepatocellular carcinomas.

Authors:  Mehmet Sayiner; Zobair M Younossi
Journal:  Hepat Oncol       Date:  2016-03-23

Review 3.  Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology.

Authors:  Sukeshi Patel Arora; Gabor Liposits; Susan Caird; Richard F Dunne; Gordon Taylor Moffat; David Okonji; Maria Grazia Rodriquenz; Divyanshu Dua; Efrat Dotan
Journal:  J Geriatr Oncol       Date:  2019-11-06       Impact factor: 3.599

Review 4.  Hepatocellular carcinoma and non-alcoholic fatty liver disease.

Authors:  Pegah Golabi; Logan Rhea; Linda Henry; Zobair M Younossi
Journal:  Hepatol Int       Date:  2019-11-07       Impact factor: 6.047

Review 5.  Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents.

Authors:  Hiroyasu Sakai; Yohei Shirakami; Masahito Shimizu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 6.  Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease.

Authors:  Alessandro Mantovani; Giovanni Targher
Journal:  Ann Transl Med       Date:  2017-07

7.  Prevention of Lipid Peroxidation-derived Cyclic DNA Adduct and Mutation in High-Fat Diet-induced Hepatocarcinogenesis by Theaphenon E.

Authors:  Ning Ma; Yanqi Hou; Heidi Coia; Marcin D Dyba; Ying Fu; M Idalia Cruz; Carlos Benitez; Garrett T Graham; Justine N McCutcheon; Yun-Ling Zheng; Bing Sun; Bhaskar V Kallakury; Junfeng Ma; Hong-Bin Fang; Deborah L Berry; Vinona Muralidaran; Fung-Lung Chung
Journal:  Cancer Prev Res (Phila)       Date:  2018-08-21

Review 8.  Caring for children with NAFLD and navigating their care into adulthood.

Authors:  Ali A Mencin; Rohit Loomba; Joel E Lavine
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-01       Impact factor: 46.802

Review 9.  TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis.

Authors:  Fengyun Xu; Changwei Liu; Dandan Zhou; Lei Zhang
Journal:  J Histochem Cytochem       Date:  2016-01-08       Impact factor: 2.479

Review 10.  Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma.

Authors:  Antonella Cammarota; Antonio D'Alessio; Tiziana Pressiani; Lorenza Rimassa; Nicola Personeni
Journal:  Drugs Aging       Date:  2021-06-21       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.